Clinical Trial

Methenamine Hippurate Following Intradetrusor OnabotulinumtoxinA Injection

Study acronym: META
Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated May 1, 2025 (before its estimated May 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to compare methenamine hippurate prophylaxis to routine antibiotic prophylaxis following onabotulinumtoxinA (BOTOX-A) injections in women with overactive bladder (OAB). Participants will be randomly selected to receive one of the two post-procedural prophylaxis medications. The primary outcome measure will be urinary tract infection (UTI) rates within 30 days from the BOTOX-A procedure. Secondary outcomes will assess patient satisfaction with the two post-procedural prophylaxis medications.
Trial Details
NCT Number NCT06953271
Lead Sponsor Women and Infants Hospital of Rhode Island
Conditions Overactive Bladder (OAB), Urinary Tract Infection (Diagnosis)
Enrollment 164 participants
Start Date 2025-05-15
Primary Completion 2026-05-01 (estimated)
Study Completion 2027-01-01 (estimated)
Updated on ClinicalTrials.gov 2025-05-01